Esperion is a pharmaceutical company that is committed to developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
Esperion has two LDL-C–lowering therapies in development: bempedoic acid and bempedoic acid plus ezetimibe fixed-dose combination. Both have defined global, pivotal, Phase 3, clinical development plans, and Esperion intends to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) in the first quarter of 2019.
Esperion owns the exclusive worldwide rights to the bempedoic acid-based franchise of products in development.
- Phase Ph1